Haimasyöpämetastaasin vastaista terapiaa kuuluu löydetyn Israelissa

• Olaparib is an FDA-approved targeted therapy for cancer. It is a PARP inhibitor, inhibiting poly ADP ribose polymerase, an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which include some ovarian, breast, and prostate cancers. In December 2014, olaparib was approved for use as a single agent by the EMA and the FDA. The FDA approval is for germline BRCA mutated advanced ovarian cancer that has received three or more prior lines of chemo

See more on en.wikipedia.org · Text under CC-BY-SA license

 

• Formula: C₂₄H₂₃FN₄O₃
• Routes of administration: Oral

• Molar mass: 435.08 g/mol g·mol−1
• Trade names: Lynparza

JPost uutinen 2.5. 2019 vahvistaa hyvää tietoa tästä lääkkeestä haimametastaaseissa niillä joilla on BRCA mutaatiot. Sirtuiiniaineenvaihdunnan kartassa  on tiet jotka  yhdistää sokeriaineenaihduntaan tämän polyADP-riboosimetabolisen reitin, nikotinamidin muodostuksen ym  ja  entsyymit kuten PARP ja PARG )https://www.researchgate.net/profile/Miguel_Fuertes/publication/5630837/figure/fig3/AS:394673161031680@1471108822080/Fig-3-PolyADP-ribose-glycohydrolase-PARG-reactivates-PARP-1-and-allows-NAD.png
http://mmbr.asm.org/content/70/3/789/F1.expansion.html#ref-339
Tämä on hyvä kartta, joka kannattaa piirtää muistiin. 

“In the history of oncology, there have been only two or three studies that have shown some benefits for pancreatic cancer,” said Dr. Raanan Berger, head of Oncology for Sheba Medical Center.

By Maayan Jaffe-Hoffman

June 2, 2019 23:25

2 minute read. 

A Chaim Sheba Medical Center researcher has discovered a potential treatment for metastatic pancreatic cancer.

“In the history of oncology, there have been only two or three studies that have shown some benefits for pancreatic cancer,” said Dr. Raanan Berger, head of Oncology for Sheba Medical Center, the country’s largest hospital, located in the Tel HaShomer neighborhood of Ramat Gan. “This is a very rare breakthrough.”
Pancreatic cancer is the 12th most common cancer worldwide, with 458,918 new cases in 2018 alone, according to a release by Sheba. It is the 4th leading cause of cancer death, and less than 3% of patients with metastatic disease survive longer than five years after diagnosis.

The research was conducted by Dr. Talia Golan, the head of Sheba’s Pancreatic Cancer Center. Specifically, her research centered on evaluating the safety and testing the efficacy of a new drug treatment regimen known as POLO in order to treat a specific type of metastatic pancreatic cancer in carriers of the BRCA 1 and BRCA 2 mutation, which runs largely in Ashkenazi Jews and typically makes these individuals susceptible to breast and ovarian cancers.

“The POLO trial using the medicine Lynparza offers potential hope for those who suffer from metastatic pancreatic cancer and have a BRCA mutation,” Dr. Golan said.

Lynparza is also known as olaparib.

“This treatment also exemplifies the advent of ‘precision medicine’ based on a specific genetic biomarker, BRCA 1 and 2,” she said.